Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Open-Label Study of Emicizumab Prophylaxis in Type III von Willebrand Disease
jRCT2071250029Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of emicizumab in Type 3 von Willebrand disease, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Number of treated bleeds over time. Started Jul 2025; status: recruiting.
02
Drugs
emicizumab
03
Conditions
Type 3 von Willebrand disease
Beyond the preview
Go deeper on jRCT2071250029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250029.